Mallinckrodt Pharmaceuticals

Mallinckrodt Pharmaceuticals, a Pharmaceutical Preparation Manufacturing company headquartered in GB, reported its 2024 emissions data. The company's Scope 1 emissions were 80,934,000 kg CO2e, with market-based Scope 2 emissions at 68,794,000 kg CO2e and location-based Scope 2 emissions at 68,201,000 kg CO2e. Scope 3 emissions included 12,136,000 kg CO2e from capital goods, 178,886,000 kg CO2e from purchased goods and services, 24,697,000 kg CO2e from fuel and energy related activities, and 22,438,000 kg CO2e from upstream transportation and distribution.

For 2023, Mallinckrodt Pharmaceuticals reported Scope 1 emissions of 81,956,000 kg CO2e and location-based Scope 2 emissions of 73,947,000 kg CO2e. In 2022, Scope 1 emissions were 80,126,000 kg CO2e and location-based Scope 2 emissions were 82,349,000 kg CO2e.

The company has set several climate commitments. It aims to reduce its Scope 1 emissions by 30% from a 2022 baseline by 2030 and also targets near-zero Scope 1 emissions by the middle of this decade (2023-2025). Similarly, Mallinckrodt Pharmaceuticals is committed to reducing its Scope 2 emissions by 30% from a 2022 baseline by 2030 and strives for near-zero Scope 2 emissions by the middle of this decade (2023-2025).

The emissions data for Mallinckrodt Pharmaceuticals is inherited from its direct parent company, Mallinckrodt Pharmaceuticals Limited.